Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 9 |
| Clinical Trials and Average Enrollment by Country | 7 | 3 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 10 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 11 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 13 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 14 | 1 |
| Clinical Trials by G7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials | 15 | 1 |
| Clinical Trials by Phase in G7 Countries | 16 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 17 | 1 |
| Clinical Trials by E7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials | 18 | 1 |
| Clinical Trials by Phase in E7 Countries | 19 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 20 | 1 |
| Clinical Trials by Phase | 21 | 2 |
| In Progress Trials by Phase | 22 | 1 |
| Clinical Trials by Trial Status | 23 | 1 |
| Clinical Trials by End Point Status | 24 | 1 |
| Subjects Recruited Over a Period of Time | 25 | 1 |
| Clinical Trials by Sponsor Type | 26 | 1 |
| Prominent Sponsors | 27 | 3 |
| Top Companies Participating in Systemic Lupus Erythematosus Therapeutics Clinical Trials | 28 | 2 |
| Prominent Drugs | 30 | 1 |
| Latest Clinical Trials News on Systemic Lupus Erythematosus | 31 | 6 |
| Aug 03, 2016: Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod | 31 | 1 |
| Jul 19, 2016: Kadmon Data Published in Science Signaling Show ROCK2 Signaling as a Key Modulator of T Follicular Helper Cell Function in Autoimmune Diseases | 31 | 1 |
| Jun 28, 2016: Anthera Provides Clinical Program Update for Blisibimod | 32 | 1 |
| Jun 20, 2016: Dalazatide as a Potential Immunotherapy for Lupus to be Presented at Immunology Conference | 33 | 1 |
| Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus | 33 | 1 |
| Jun 08, 2016: New Phase III data shows greater treatment response with GSK s Benlysta (belimumab) vs placebo in patients with highly active SLE | 34 | 1 |
| Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016) | 35 | 1 |
| Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study | 36 | 1 |
| Jun 02, 2016: AbbVie Highlights on Venetoclax (ABT-199) at the Annual European Congress of Rheumatology (EULAR 2016) | 36 | 1 |
| Clinical Trial Profile Snapshots | 37 | 353 |
| Appendix | 390 | 3 |
| Abbreviations | 390 | 1 |
| Definitions | 390 | 1 |
| Research Methodology | 391 | 1 |
| Secondary Research | 391 | 1 |
| About GlobalData | 392 | 1 |
| Contact Us | 392 | 1 |
| Disclaimer | 392 | 1 |
| Source | 393 | 1 |